US98956P1021 - Common Stock
Tesla upgraded, MongoDB initiated: Wall Street's top analyst calls
/PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE: ZBH and SIX: ZBH), a global medical technology leader, today received the CE Mark for its Persona® Revision...
The company is well known for its hip and knee replacements. Full-year sales will take an unexpected hit.
ZBH stock results show that Zimmer Biomet Holdings beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
At their 52-week lows, these undervalued healthcare stocks present a favorable return supported by healthcare spending tailwinds.
The company spun out from Zimmer Biomet in 2022. Now, it's a possible takeover candidate.